Best AI Mental Health Tools 2026
Reviewing Woebot Health, Spring Health, Blueprint, Wysa, SimplePractice, and Elomia to find which AI mental health tools actually deliver clinical outcomes for therapists, behavioral health clinics, and HR teams — and which leave your organization exposed to regulatory risk and unvalidated claims.
Tool Verdicts
Woebot Health
ShipMost clinically validated AI mental health chatbot — 15+ peer-reviewed RCTs, FDA Breakthrough Device designation, and proven efficacy as an evidence-based adjunct to mental healthcare at scale
Woebot Health is the most rigorously studied conversational AI mental health platform on the market, distinguished by a scientific foundation that is rare in the consumer mental health space. Founded by Dr. Alison Darcy, a Stanford clinical researcher, Woebot is built on cognitive behavioral therapy (CBT) principles and has accumulated over 15 randomized controlled trials published in peer-reviewed journals — making it the only AI mental health tool with a clinical evidence base comparable to traditional therapeutic interventions. The platform delivers structured CBT exercises, mood tracking, psychoeducation modules, and conversational check-ins through a chatbot interface available 24/7, providing mental health support at the exact moments when licensed clinicians are unavailable: nights, weekends, and the gaps between scheduled appointments. Woebot received FDA Breakthrough Device designation for its work in treating depression and substance use disorders, placing it in a distinct regulatory category from the hundreds of wellness apps that make vague mental health claims without clinical evidence. This designation reflects FDA's acknowledgment that Woebot's evidence base meets the bar for review as a digital therapeutic rather than a general wellness application. Health systems including the Cleveland Clinic and Ochsner Health have deployed Woebot as a clinical adjunct — available to patients between in-person appointments to reinforce therapeutic work, build skill practice between sessions, and provide continuity of care for patients on waitlists or with limited access to in-person therapy. Woebot's enterprise and health system deployments serve the specific need for scalable mental health support that cannot be met by growing the supply of licensed clinicians alone. Employer EAP programs, health systems with long therapy waitlists, and collegiate mental health programs face demand that cannot be satisfied through traditional staffing. Woebot's evidence base and FDA designation give procurement teams — healthcare executives, benefits directors, and institutional review boards — the clinical validation they need to justify deployment at scale. The platform's clinical partnership model (deployed alongside licensed clinicians rather than replacing them) positions Woebot correctly for the compliance requirements of institutional mental health programs.
FDA Breakthrough Device designation and 15+ peer-reviewed RCTs provide a clinical evidence base that institutional buyers — health systems, employer benefits teams, university counseling centers — require before deploying any mental health tool at scale. The evidence is particularly strong for depression, anxiety, and substance use populations, with published efficacy data across these major diagnostic categories. The 24/7 availability model fills the care gap between in-person appointments, directly addressing the patient abandonment and crisis escalation that occurs when traditional outpatient therapy cannot provide between-session support. Health system and employer deployments validate Woebot's ability to operate within institutional procurement and compliance requirements, including HIPAA-compliant data handling and integration with existing care coordination workflows.
Woebot is not a substitute for licensed clinical care and cannot diagnose, treat, or prescribe — the platform is designed as a clinical adjunct, and organizations expecting it to independently manage complex mental health presentations (severe depression, psychosis, active suicidality) will find it insufficient as a standalone intervention. The conversational AI experience can feel repetitive for users who engage with Woebot over extended periods: the structured CBT exercise library, while evidence-based, does not adapt as fluidly to individual clinical presentations as a skilled human therapist. Pricing for enterprise deployments is custom and can be substantial: health systems and large employers face per-member-per-month costs that require volume commitments and executive sponsorship to justify.
Spring Health
ShipLeading AI-powered employee mental health benefits platform — ML-matched therapy access, psychiatry, and EAP replacement with published clinical outcomes for enterprise HR teams
Spring Health is the dominant AI-powered employee mental health benefits platform in the enterprise market, replacing legacy EAP (Employee Assistance Program) programs with a data-driven mental health navigation layer that uses machine learning to match employees with the most clinically appropriate provider from a network of 10,000+ licensed therapists, psychologists, and psychiatrists. The platform's Precision Mental Healthcare model analyzes each employee's clinical profile — including screening assessment results, preferences, and treatment history — to surface matched provider recommendations that reduce the number of sessions needed to achieve meaningful outcomes, directly addressing the utilization and engagement gaps that make traditional EAP programs chronically underused by the employees who need them most. Spring Health's outcomes data distinguishes it from benefit brokers and EAP administrators that measure utilization without measuring clinical impact. The platform publishes member outcome data showing meaningful reductions in PHQ-9 depression scores and GAD-7 anxiety scores, and provides HR teams with population-level mental health analytics that comply with HIPAA's privacy requirements — aggregate reporting that helps benefits leaders understand program effectiveness without accessing individual employee data. This outcomes infrastructure is what enterprise buyers at Fortune 500 companies require to justify mental health benefits investment to finance teams and boards increasingly focused on workforce mental health ROI. The platform's provider network includes therapists, psychologists, psychiatrists, and coaches, giving employees access to the full mental healthcare spectrum — from coaching for work-related stress to psychiatric medication management for serious mental illness — through a single benefits platform. Spring Health handles scheduling, billing, and out-of-pocket cost navigation, removing the administrative barriers that prevent eligible employees from accessing mental health benefits. The company has raised over $500M and serves clients including Google, Microsoft, Nike, and General Mills — employer-brand names that validate Spring Health's enterprise readiness and institutional trust for HR procurement teams evaluating credibility alongside capability.
ML-powered provider matching that uses clinical profile data to reduce time-to-appropriate-care is Spring Health's core differentiator from traditional EAP programs that rely on first-available or self-selected provider matching — evidence shows matched care reduces the number of sessions required to achieve clinical outcomes, a direct cost reduction alongside health improvement. The 10,000+ provider network and same-week appointment availability address the most common EAP failure mode: employees who call for help and then wait weeks for an appointment, abandoning before treatment begins. Published outcomes data and HIPAA-compliant population analytics give HR leaders and CFOs the evidence needed to justify mental health benefits investment and demonstrate program ROI to boards and finance teams.
Spring Health is designed for mid-market to enterprise employers (typically 1,000+ employees) — small businesses without dedicated HR teams and benefits administration infrastructure will find the platform over-engineered for their needs and the sales process misaligned with their purchasing timelines. The platform's ML matching model is most effective for common mental health presentations (depression, anxiety, work stress) in the US — employers with large international workforces will find Spring Health's provider network and clinical model most relevant to US-based employees, with coverage gaps in non-US markets. The transition from a legacy EAP to Spring Health requires employee communication, onboarding, and change management investment that benefits teams who underestimate this cost will see reflected in slower adoption than the platform's utilization benchmarks suggest.
Blueprint
ShipBest AI-assisted clinical documentation and outcome measurement for mental health practices — automated progress notes, treatment planning, and PHQ/GAD tracking that cuts therapist admin burden by 30-60 minutes per day
Blueprint is an AI-assisted clinical documentation and outcome measurement platform built specifically for licensed mental health clinicians — therapists, psychologists, social workers, and behavioral health clinicians — who spend significant portions of their working hours on administrative documentation rather than direct client care. The platform automates progress note generation, treatment plan drafting, and outcome measure administration (PHQ-9, GAD-7, PCL-5, and 20+ validated assessment instruments), reducing the documentation burden that research consistently identifies as a primary driver of therapist burnout and attrition. Blueprint was formed through the combination of therapy documentation software with behavioral health practice management tools, creating a platform that covers the clinical workflow from intake assessment through progress note completion to outcome reporting. Blueprint's AI progress note generation works by processing session documentation inputs — structured note templates, clinician annotations, or voice-to-text session summaries — and generating HIPAA-compliant progress notes in SOAP (Subjective, Objective, Assessment, Plan) or DAP (Data, Assessment, Plan) format that clinicians review, edit, and sign. The key insight is that even partial automation of note generation — reducing 20-30 minute documentation sessions to 5-10 minutes of clinician review — creates meaningful administrative relief at scale in group practices where documentation overhead accumulates across dozens of clinicians. Blueprint's outcome measurement module administers standardized assessments to clients before sessions, auto-scores results, tracks scores over time, and integrates outcome data into progress notes — creating the continuous outcome monitoring infrastructure that value-based care contracts and behavioral health accreditation increasingly require. Blueprint is positioned for behavioral health group practices, outpatient mental health clinics, and community mental health centers that need clinical documentation infrastructure at the practice level rather than individual clinician tools. The platform's HIPAA compliance, EHR integration capabilities (Epic, Athena, and behavioral health-specific EHRs), and multi-clinician management features make it appropriate for practice administrators and clinical directors responsible for documentation quality and compliance across their entire clinician workforce. For group practices evaluating ways to reduce overhead costs while improving clinician satisfaction and retention, Blueprint's documentation automation provides a direct labor cost reduction alongside meaningful quality-of-life improvement for clinical staff.
Automated progress note generation with clinician review is the most direct path to reducing the documentation burden that drives therapist burnout — practices that have deployed Blueprint consistently report clinician time savings of 30-60 minutes per day on documentation, which compounds across a clinician's full caseload and translates directly to more capacity for client care. Outcome measurement automation (PHQ-9, GAD-7, and 20+ standardized instruments) creates the continuous assessment data that value-based care contracts, NCQA accreditation, and behavioral health quality reporting increasingly require — practices without systematic outcome tracking are disadvantaged in VBC contract negotiations with health systems and payers. HIPAA compliance, EHR integration, and multi-practice management features make Blueprint appropriate for group practices and behavioral health organizations that need enterprise-grade documentation infrastructure, not just individual clinician tools.
Blueprint is a clinical documentation and outcome measurement platform — it is not a client-facing mental health intervention, an AI therapy chatbot, or a patient engagement tool. Organizations looking for AI tools that directly support mental health care delivery to clients (rather than administrative support for clinicians) should evaluate Woebot, Wysa, or Spring Health instead. The platform requires clinician adoption and workflow change to realize its value: practices with high clinician turnover, strong resistance to documentation workflow changes, or EHR environments where integration is difficult will find adoption slower and ROI timelines longer than the platform's benchmarks suggest.
Wysa
ShipClinically validated AI mental health app with CBT, DBT, and mindfulness — NHS-validated, deployed by enterprise EAPs, and cost-effective for high-volume population mental health support
Wysa is an AI-powered mental health support app that delivers evidence-based therapeutic exercises drawing from cognitive behavioral therapy (CBT), dialectical behavior therapy (DBT), mindfulness-based stress reduction (MBSR), and behavioral activation through a conversational AI interface. The platform is designed as a scalable mental health resource for the large gap between 'I am struggling but not in crisis' and 'I am ready for a therapist appointment' — a population that exists in enormous numbers in every workplace and healthcare system but for whom traditional mental health services are inaccessible due to cost, availability, waitlists, or stigma. Wysa addresses this access gap by delivering structured, evidence-based exercises 24/7 at a cost-per-engagement that traditional care delivery cannot approach. Wysa's clinical validation distinguishes it from the majority of mental health apps that make therapeutic claims without published evidence. The platform has been evaluated in multiple peer-reviewed studies, with particularly strong evidence for its use in adolescent mental health, workplace well-being programs, and chronic disease populations. The UK's National Health Service (NHS) has included Wysa in its validated digital health library, providing one of the most rigorous external validations available for a digital mental health tool — NHS digital health evaluation requires clinical evidence review, safety assessment, and data governance standards that most consumer mental health apps cannot meet. This NHS validation gives enterprise procurement teams, clinical advisory boards, and healthcare executives a credible third-party endorsement to reference in deployment justification. For enterprise EAP programs and healthcare systems seeking cost-effective scale in mental health access, Wysa's engagement economics are compelling: the platform can deliver evidence-based mental health support to thousands of users simultaneously at a cost-per-engagement that is orders of magnitude lower than in-person therapy sessions. Wysa includes a human coaching escalation layer — users who engage with AI support and need human contact can connect with Wysa-trained coaches, providing a stepped care model that matches support intensity to clinical need. The platform's safety protocols include passive suicidality screening with crisis resource provision and care escalation, addressing the primary regulatory and liability concern that institutional buyers raise about deploying AI mental health tools at population scale.
NHS digital health library inclusion validates Wysa's clinical evidence and safety standards against one of the world's most rigorous health technology evaluation frameworks — a third-party endorsement that enterprise procurement teams, clinical advisory boards, and healthcare executives can rely on for institutional deployment justification without conducting their own evidence review. Evidence-based CBT, DBT, and mindfulness content library is genuinely broad: Wysa covers anxiety, depression, stress, sleep, relationships, and chronic illness mental health support through structured, research-backed exercises rather than generic wellness content. Low cost-per-engagement makes Wysa economically viable for large-scale population mental health programs where per-session therapy costs would be prohibitive — EAPs, student wellness programs, and workforce mental health initiatives serving thousands of members can reach much larger populations with Wysa than with traditional provider-based benefits.
Wysa is a support tool rather than a treatment platform — it is appropriate for mild to moderate mental health challenges and wellbeing support, but is not designed or validated for acute mental health crises, severe psychiatric presentations, or clinical populations requiring diagnosis and prescription medication management. The conversational AI interaction model is effective for users who engage consistently with structured exercises, but passive or disengaged users who do not complete modules will not derive therapeutic benefit — Wysa requires user motivation and engagement to deliver value, and organizations should plan active engagement campaigns alongside deployment to drive utilization. Enterprise customization options are more limited than Spring Health's platform — organizations that need deep branding, custom clinical content modules, or complex EHR integration with existing health system workflows will find Wysa less flexible than purpose-built enterprise health platforms.
SimplePractice
WatchlistMarket-leading practice management for independent therapists with AI-assisted note-taking — strong for private practice operations but primarily a workflow platform, not a purpose-built AI clinical intervention
SimplePractice is the dominant practice management software platform for independent licensed mental health therapists, private practice counselors, and small behavioral health group practices in the United States. The platform covers the full private practice workflow: intake paperwork, scheduling and appointment reminders, telehealth session delivery, secure messaging, insurance billing, claims management, and clinical documentation — providing the operational infrastructure that allows therapists to run compliant, organized practices without hiring dedicated administrative staff. With over 200,000 clinicians on the platform, SimplePractice holds unambiguous category leadership for private practice management in the behavioral health space and benefits from strong network effects in insurance payer connectivity and community knowledge. SimplePractice has introduced AI-assisted features in 2025-2026, with AI note-taking as the headline capability: the platform can process session audio (with client consent), generate draft progress notes, and auto-populate clinical documentation templates — directly addressing the administrative burden that therapists consistently cite as their primary source of occupational stress. The AI scheduling optimization and automated insurance billing features reduce the business operations overhead that private practice clinicians manage alongside their clinical work. These are meaningful quality-of-life improvements for solo practitioners who previously spent 2-3 hours per client week on non-clinical administration tasks that erode both clinical capacity and work satisfaction. The reason SimplePractice earns a watchlist verdict rather than a ship verdict is that it is fundamentally a practice management platform that has added AI features — it is not a purpose-built AI mental health tool, AI therapy adjunct, or evidence-based digital mental health intervention. The AI capabilities are workflow automation features (note generation, scheduling, billing) rather than clinical decision support, outcome measurement systems, or patient-facing therapeutic tools. Organizations evaluating AI mental health tools specifically for clinical impact — improved patient outcomes, mental health access expansion, or evidence-based therapeutic interventions — should look to Blueprint, Woebot, Wysa, or Spring Health. SimplePractice belongs on the evaluation list for any independent therapist or small group practice needing practice management infrastructure; it is the wrong primary evaluation target for buyers whose primary goal is AI-driven clinical impact.
Dominant market position with 200,000+ clinicians validates product-market fit for independent therapist practice management — the platform's breadth of feature coverage and large user community create strong network effects in integrations, insurance payer connectivity, and community knowledge that smaller competitors cannot match for the private practice segment. AI note-taking feature directly addresses the documentation burden that drives therapist burnout, providing a meaningful quality-of-life improvement that is immediately visible to clinicians in daily practice with minimal workflow disruption. Integrated telehealth, billing, scheduling, and documentation in a single platform eliminates the multi-tool workflow fragmentation that characterizes typical private practice technology stacks and creates ongoing administrative overhead.
SimplePractice is practice management software with AI workflow features, not a clinical AI platform — organizations specifically evaluating AI for mental health clinical impact (patient outcomes, scalable care delivery, evidence-based digital therapeutics) should lead their evaluation with Blueprint for documentation automation, Spring Health for EAP benefits, or Woebot and Wysa for direct patient intervention tools. Enterprise behavioral health organizations, health systems, and large group practices will find SimplePractice's feature set and integration capabilities insufficient for their scale — the platform is optimized for the solo-to-small-group private practice segment and lacks the enterprise EHR integration depth, population analytics, administrative hierarchy, and compliance reporting that larger organizations require.
Elomia
SkipAI therapy chatbot without the clinical validation, regulatory standing, or evidence base to justify selection over Woebot or Wysa — not appropriate for institutional deployment
Elomia is an AI-powered mental health chatbot marketed as an accessible alternative to traditional therapy, offering conversational mental health support through a chatbot interface that uses natural language processing to engage users in emotionally supportive dialogues. The app targets users experiencing anxiety, depression, stress, and relationship difficulties with an interface modeled on therapeutic conversation — the chatbot responds empathetically, asks follow-up questions, and provides basic coping strategies in a format designed to feel supportive and non-judgmental. For individual users seeking a low-friction entry point to mental health support, Elomia presents as approachable with minimal setup friction and a direct-to-consumer pricing model that makes it accessible without insurance or referral requirements. The fundamental problem with Elomia is the absence of clinical validation. While Woebot and Wysa have invested heavily in peer-reviewed RCT evidence to substantiate their therapeutic claims, Elomia has not published randomized controlled trials establishing that its conversational AI produces meaningful outcomes for anxiety, depression, or other mental health conditions. The AI therapy space is particularly high-stakes for this gap: mental health tools that make implicit or explicit therapeutic claims without evidence can expose users to the risk of delayed appropriate care — users who believe they are receiving effective AI therapy may not seek licensed clinical care they actually need. In the US regulatory environment, the FDA has signaled increasing scrutiny of software-as-medical-device products that make wellness or therapeutic claims without cleared evidence, creating compliance risk for institutional buyers considering Elomia for employee or patient programs. Institutional buyers — health systems, employers, EAPs, university counseling centers — should not deploy Elomia when validated alternatives exist at comparable or lower cost. The evaluation criteria that institutional procurement requires — peer-reviewed RCT evidence, FDA regulatory clarity, HIPAA-compliant data handling with documented BAA processes, crisis detection and escalation protocols validated through clinical review, and enterprise support infrastructure — are areas where Elomia does not provide the documentation and evidence transparency that Woebot and Wysa offer. For individual consumers who find the app helpful for general stress and self-reflection, Elomia may provide some subjective benefit, but the clinical and institutional mental health market should look elsewhere.
Low barrier to entry with consumer-friendly pricing and a simple, accessible interface — Elomia requires no clinical referral, no insurance, and no waitlist, making it immediately accessible to users who want to explore conversational mental health support without commitment or upfront cost. Natural language conversational interface provides a non-judgmental, available-at-any-time outlet for emotional processing that some users find helpful for managing day-to-day stress and self-reflection outside of formal clinical contexts. App accessibility on iOS and Android with no special technical requirements removes friction for users who are not ready to engage with more structured clinical platforms or commit to a therapy relationship.
No published randomized controlled trials or peer-reviewed outcome data to support therapeutic efficacy claims — Elomia cannot demonstrate to institutional buyers, clinical advisory boards, or procurement teams that its AI intervention produces measurable mental health improvements, which is the minimum evidentiary bar for institutional deployment in any responsible mental health program. Regulatory status is ambiguous: Elomia does not hold FDA Breakthrough Device designation, FDA clearance, or equivalent regulatory standing, creating compliance uncertainty for health system and employer buyers in a regulatory environment where FDA scrutiny of AI mental health tools is increasing. Better-validated alternatives (Woebot, Wysa) are available at comparable or lower per-user cost and provide evidence-based clinical content with established safety and crisis escalation protocols — there is no dimension on which Elomia outperforms its validated competitors for institutional deployment.
Decision Matrix: AI Mental Health Tools Compared
How each platform performs across the dimensions that matter most for clinical, compliance, and operational buyers. ★★★ = strong, ★★ = adequate, ★ = limited, – = not applicable.
| Tool | Clinical Validation | Privacy / HIPAA | Provider Workflow | Patient Engagement | Crisis Detection | Insurance Coverage |
|---|---|---|---|---|---|---|
| Woebot Health | ★★★ | ★★★ | ★★ | ★★★ | ★★★ | ★★ |
| Spring Health | ★★★ | ★★★ | ★★★ | ★★★ | ★★★ | ★★★ |
| Blueprint | ★★ | ★★★ | ★★★ | ★ | ★ | ★★ |
| Wysa | ★★★ | ★★★ | ★★ | ★★★ | ★★★ | ★ |
| SimplePractice | ★ | ★★★ | ★★★ | ★★ | ★ | ★★★ |
| Elomia | – | ★ | – | ★★ | ★ | – |
What AI Mental Health Vendors Won't Tell You
- "Clinically validated" means very different things across vendors. The mental health app space uses "evidence-based," "clinically validated," and "proven" as marketing terms with wildly inconsistent evidentiary backing. A single small pilot study with 50 participants and no control group gets packaged as "clinically proven" by vendors who know procurement teams rarely drill into the methodology. True clinical validation requires randomized controlled trials with adequate sample sizes, active control groups, pre-registered outcome measures, and peer-reviewed publication. Before accepting any vendor's clinical validation claims, ask specifically: How many RCTs? What were the sample sizes? Were they published in peer-reviewed journals? What was the control condition? Woebot and Wysa have strong answers; most other vendors do not.
- A signed BAA is not the same as genuine HIPAA compliance. Every vendor in this space will sign a Business Associate Agreement — it is a contractual baseline, not evidence of actual security practice. The substantive questions are: What encryption standards protect data at rest and in transit? How is access to sensitive mental health data controlled internally? What is the breach notification timeline and process? Is employee access to patient conversation data logged and audited? How is mental health data separated from general analytics data that might be used for product improvement? HIPAA compliance in mental health technology requires a thorough technical review, not just a signed agreement. Require a third-party SOC 2 Type II report and a detailed data flow diagram before deploying any AI mental health tool at institutional scale.
- Crisis detection protocols vary enormously and most are not clinically reviewed. Every AI mental health vendor claims to have crisis detection and escalation capabilities, but the implementation ranges from validated clinical instruments (embedded PHQ-9 items, standardized suicidality screening) to basic keyword matching (flagging messages containing the word "suicide" or "harm") with no clinical review of the protocol design. The difference matters enormously: inadequate crisis detection can create a false sense of safety for institutional buyers while leaving users in acute distress without appropriate escalation. Before deployment, require clinical leadership to review the crisis detection protocol in detail — what triggers escalation, what resources are provided, how does the escalation reach a human responder, and has the protocol been validated against clinical standards such as the Columbia Suicide Severity Rating Scale?
- Engagement metrics are not clinical outcomes — and vendors know this. Vendors will present daily active users, session completion rates, app store ratings, and time-in-app as evidence of effectiveness. These engagement metrics are real and relevant, but they are not clinical outcomes. A user can engage with an AI mental health app 30 minutes per day for three months and show no measurable improvement in PHQ-9 score, no reduction in anxiety symptoms, and no change in functional impairment. When evaluating AI mental health tools for institutional deployment, insist on clinical outcome data: what is the average PHQ-9 score change at 8 weeks for users who completed the program? What percentage of users who started with moderate-to-severe depression scores achieved reliable improvement? If the vendor cannot provide this data, treat the platform as unvalidated regardless of its engagement metrics or user testimonials.
AI Mental Health Tool Evaluation Checklist
Use this checklist when evaluating AI mental health tools for institutional deployment, EAP replacement, or clinical practice integration.
What peer-reviewed clinical evidence (randomized controlled trials, published outcome studies) supports the tool's efficacy claims for your target population — anxiety, depression, substance use, or general wellness?
Does the vendor provide a signed Business Associate Agreement (BAA) and documented HIPAA compliance program, including data encryption, access controls, employee training records, and breach incident response procedures?
What are the crisis detection and escalation protocols — how does the platform identify users in acute distress, what crisis resources are provided, and how does escalation to human care reach the appropriate clinician or crisis line?
Does the platform integrate with your existing EHR systems (Epic, Athena, behavioral health-specific EHRs) and does integration enable bidirectional data exchange or only one-directional data import?
If the tool includes a provider network, what is the network depth and appointment availability in your target geography — and what is the average time-to-first-appointment for a new member seeking care?
Is the platform compatible with value-based care contract requirements — does it administer validated outcome measures (PHQ-9, GAD-7, PCL-5), produce population-level outcome analytics, and generate the clinical quality data that payer contracts require?
What data privacy and patient confidentiality protections govern user-generated content — is conversation data used for AI model training, shared with third parties, or retained beyond the care relationship, and how does the vendor handle data subject access requests?
What implementation timeline, clinician training requirements, and change management support does the vendor provide — and what adoption benchmarks do comparable organizations achieve in the first 90 days post-deployment?
Does the tool have regulatory clarity for your deployment context — FDA Breakthrough Device designation, FDA clearance, NHS digital health library inclusion, or equivalent third-party validation that your clinical advisory board will accept as evidence of safety and efficacy?
What is the total cost structure including implementation fees, per-member-per-month rates, overage pricing, and annual contract minimums — and does the vendor provide outcomes-based pricing or performance guarantees tied to clinical results?
Know an AI mental health tool we missed?
We review new tools monthly. Submit for consideration.